Ariad Pharmaceuticals Inc fka ARIA

[gr8db8]

The next step in their research was to identify next-generation ALK inhibitors able to overcome alectinib resistance caused by the newly identified mutations. From these studies, they found that ceritinib, approved by the FDA in April 2014 for the treatment of ALK-positive NSCLC resistant to crizotinib, can overcome resistance to alectinib. AP26113, an investigational drug currently in clinical trials, was also able to overcome alectinib resistance.

Shaw and colleagues took this knowledge back to the bedside, to a patient whose cancer relapsed on crizotinib first, and then on alectinib. They treated this patient with ceritinib, and this patient had a partial response lasting for seven months.

“For patients like Rocky, the inevitable question is, ‘What do we do after ceritinib?’” said Shaw in an interview. “Fortunately, our study suggests that you may be able to use another next-generation ALK inhibitor <my response: like AP26113?> as the next treatment. Depending on the resistance mechanisms the patients’ tumors develop, it may be possible for them to derive clinical benefit from a series of different ALK inhibitors.”


http://blog.aacr.org/findings-open-doors-rational-lung-cancer-treatment-strategies/